MPM BioImpact — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in
BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in
Board seatTodd Foley· per SEC Form D
Co-investorsPfizer Venture InvestmentsBiotechnology Value FundMirae Asset Venture InvestmentPfizer VenturesPolaris PartnersTaiho Ventures, LLC
BiotechOklahoma City, US
Russell P. Rother(Executive Officer, Director, Promoter)Scott A. Rollins(Executive Officer, Director, Promoter)Philip Jones(Director)Richard Alvarez(Executive Officer)
BoardMichael Moradi-Araghi(Director)
Board seatTodd Foley· per SEC Form D · $15.6M raise · filed Oct 2025
Co-investorsCortado Ventures
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)Gregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Board seatAnsbert K. Gadicke· per SEC Form D
Co-investorsFemHealth VenturesMitsui Global InvestmentNovo Holdings
BiotechHealthtechSan Diego, US
Brent J. Warner(Executive Officer, Director)XIN JIANG(President & CEO)HANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)
BoardTIM LOHOFF(Director)EDWARD HURWITZ(Director)
Co-investorsDigitalis VenturesDroia VenturesForbionLightspeed Venture PartnersNovartis Venture FundVida Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.